Poolbeg has announced that it has received the requisite regulatory approvals to start its LPS challenge clinical trial with POLB 001, a p38 MAP Kinase inhibitor and a potential treatment for the hyperinflammatory response that can occur with severe influenza. The clinical trial activities will formally commence on 22 July, meaning that patient recruitment should commence and the target of a data read-out before the end of 2022 remains on track. If successful, the study could lay the foundation ....
20 Jul 2022
Poolbeg Pharma - POLB 001 LPS challenge trial on track
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Poolbeg Pharma - POLB 001 LPS challenge trial on track
Poolbeg Pharma PLC (POLB:LON) | 10.6 0 2.4% | Mkt Cap: 53.0m
- Published:
20 Jul 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
8
Poolbeg has announced that it has received the requisite regulatory approvals to start its LPS challenge clinical trial with POLB 001, a p38 MAP Kinase inhibitor and a potential treatment for the hyperinflammatory response that can occur with severe influenza. The clinical trial activities will formally commence on 22 July, meaning that patient recruitment should commence and the target of a data read-out before the end of 2022 remains on track. If successful, the study could lay the foundation ....